Myriad Genetics, Inc. provided financial guidance for 2023 and 2024. For 2023, the company expected revenue of $747 - $753 million, Raised the 2023 revenue guidance range. Revenue growth range now 10% - 11% over 2022. GAAP loss per share of $3.15 - $3.07
Myriad Genetics introduces its 2024 revenue guidance of between $815 million and $835 million, or 9% - 11% growth over the mid-point of the 2023 revenue guidance range.